Pfizer’s Norvasc Does Not Infringe Synthon Patent, Court Finds
This article was originally published in The Pink Sheet Daily
Executive Summary
The company’s revenues stemming from its blockbuster hypertension treatment remain safe after Synthon had challenged its manufacturing process.